Azeem Rizvi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Azeem Rizvi has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ankur Vashishtha
Department of Medical Laboratory Technology, Sharda School of Allied Health Sciences, Sharda University, Greater Noida, Uttar Pradesh, 201310, India
1 shared publication - Asif Ali
Department of Medical Lab Science, School of Medical and Allied Sciences, Sanskriti University, Mathura, Uttar Pradesh, 281401, India
1 shared publication - Javed Siddiqui
School of Medical and Allied Health Sciences (Medical Laboratory Technology) Galgotias University Greater Noida India
1 shared publication - Maajid Mohi Ud Din Malik
Department of Radiology and Imaging Technology Dr. D. Y. Patil School of Allied Health Sciences, Dr. D. Y. Patil Vidyapeeth (Deemed to be University) Pune Maharashtra India
1 shared publication Prashant Kumar Singh
Department of Medical Lab Science, School of Medical and Allied Sciences, Sanskriti University, Mathura, Uttar Pradesh, 281401, India
1 shared publication- Prigya Sharma
Sharda School of Life Science, Sharda University, Greater Noida, Uttar Pradesh, 201310, India
1 shared publication
Latest Publications
- 13 October 2026
- Published by Bentham Science Publishers Ltd. in Current Signal Transduction Therapy
- Vol. 21, 1-12
Role of Liquid Biopsy in Cancer Diagnosis: A Comparative Evaluation with Conventional Techniques
Introduction: Tissue biopsy and histopathological evaluation-considered the gold standard-are traditionally used for cancer diagnosis; however, these procedures are invasive and limited in their ability to accurately capture tumor heterogeneity. Liquid biopsy has emerged as a minimally invasive alternative that enables molecular characterization through circulating tumor- derived biomarkers. Methods: This review critically evaluates the biological basis, technical platforms, and clinical applications of liquid biopsies, including circulating tumor DNA (ctDNA), Circulating Tumor Cells (CTCs), exosomes, and other circulating biomarkers. A comparative analysis with conventional tissue biopsies was conducted based on invasiveness, diagnostic accuracy, assessment of tumor heterogeneity, capacity for timely monitoring, cost-effectiveness, and clinical utility. Results: Liquid biopsy offers significant advantages regarding minimal invasiveness, repeatability, and the dynamic monitoring of tumor progression and treatment response. It holds potential for detecting minimal residual disease and emerging resistance mutations. However, challenges remain concerning analytical sensitivity, test standardization, cost, and regulatory implementation in early-stage cancer. Tissue biopsy continues to provide essential morphological, histological, and staging information. Discussion: Current evidence indicates that liquid biopsy is a complement to, rather than a substitute for, traditional tissue-based diagnosis. Integrating molecular profiling with conventional histopathology can advance the precision oncology approach. Conclusion: 'Liquid biopsy' represents a revolutionary advancement in cancer testing. While it holds great promise for real-time disease monitoring and personalized therapy, its optimal clinical role lies in complementing existing diagnostic techniques rather than completely replacing them.
- 13 October 2026
- Published by Bentham Science Publishers Ltd. in Current Signal Transduction Therapy
- Vol. 21, 1-12
Role of Liquid Biopsy in Cancer Diagnosis: A Comparative Evaluation with Conventional Techniques
Introduction: Tissue biopsy and histopathological evaluation-considered the gold standard-are traditionally used for cancer diagnosis; however, these procedures are invasive and limited in their ability to accurately capture tumor heterogeneity. Liquid biopsy has emerged as a minimally invasive alternative that enables molecular characterization through circulating tumor- derived biomarkers. Methods: This review critically evaluates the biological basis, technical platforms, and clinical applications of liquid biopsies, including circulating tumor DNA (ctDNA), Circulating Tumor Cells (CTCs), exosomes, and other circulating biomarkers. A comparative analysis with conventional tissue biopsies was conducted based on invasiveness, diagnostic accuracy, assessment of tumor heterogeneity, capacity for timely monitoring, cost-effectiveness, and clinical utility. Results: Liquid biopsy offers significant advantages regarding minimal invasiveness, repeatability, and the dynamic monitoring of tumor progression and treatment response. It holds potential for detecting minimal residual disease and emerging resistance mutations. However, challenges remain concerning analytical sensitivity, test standardization, cost, and regulatory implementation in early-stage cancer. Tissue biopsy continues to provide essential morphological, histological, and staging information. Discussion: Current evidence indicates that liquid biopsy is a complement to, rather than a substitute for, traditional tissue-based diagnosis. Integrating molecular profiling with conventional histopathology can advance the precision oncology approach. Conclusion: 'Liquid biopsy' represents a revolutionary advancement in cancer testing. While it holds great promise for real-time disease monitoring and personalized therapy, its optimal clinical role lies in complementing existing diagnostic techniques rather than completely replacing them.
- Open Access
- 12 October 2026
- Published by Wiley in Journal of Clinical Laboratory Analysis
- p. e70383
Comments on: Flow Cytometric Profiling Reveals Platelet Dysfunction and Impaired Immune Communication in Acute and Chronic Cerebrovascular Disease
- 12 October 2026
- Published by Wiley in Journal of Clinical Laboratory Analysis
- p. e70383
Open AccessComments on: Flow Cytometric Profiling Reveals Platelet Dysfunction and Impaired Immune Communication in Acute and Chronic Cerebrovascular Disease